急性ST段抬高心肌梗死溶栓治疗中国专家共识(2009年版)

[1] 节假日对ST段抬高心肌梗死院内再灌注延迟的影响 [J]. 中国介入心脏病学杂志, 2008, (02) : 91 - 94

[2] 中国ST段抬高的急性心肌梗死临床特征及治疗现状 [J]. 中华医学杂志, 2005, (31) : 2176 - 2182

[3] Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction （CARESS-in-AMI）: an open, prospective, randomised, multicentre trial[J] . Carlo Di Mario,Dariusz Dudek,Federico Piscione,Waldemar Mielecki,Stefano Savonitto,Ernesto Murena,Konstantinos Dimopoulos,Antonio Manari,Achille Gaspardone,Andrzej Ochala,Krzysztof Zmudka,Leonardo Bolognese,Philippe Gabriel Steg,Marcus Flather.The Lancet . 2

[4] Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction[J] . Harindra C. Wijeysundera,Ram Vijayaraghavan,Brahmajee K. Nallamothu,JoAnne M. Foody,Harlan M. Krumholz,Christopher O. Phillips,Amir Kashani,John J. You,Jack V. Tu,Dennis T. Ko.Journal of the American College of Cardiology . 2007 (4)

[5] A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: The TUCC trial[J] . Allan M. Ross,Runlin Gao,Karin S. Coyne,Jilin Chen,Kangbao Yao,Yuejin Yang,Xuewen Qin,Shubin Qiao,Min Yao.American Heart Journal . 2001 (2)

[6] Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial[J] . The Lancet . 2001 (9296)

[7] Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial[J] . The Lancet . 2001 (9272)

[8] Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction[J] . The Lancet . 2001 (9282)

[9] Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999[J] . William J. Rogers,John G. Canto,Costas T. Lambrew,Alan J. Tiefenbrunn,Becky Kinkaid,David A. Shoultz,Paul D. Frederick,Nathan Every.Journal of the American College of Cardiology . 2000 (7)

[10] Mortality Within 24 Hours of Thrombolysis for Myocardial Infarction: The Importance of Early Reperfusion[J] . Neal S. Kleiman,Harvey D. White,E. Magnus Ohman,Allan M. Ross,Lynn H. Woodlief,Robert M. Califf,David R. Holmes,Eric Bates,Matthias Pfisterer,Alec Vahanian,Eric J. Topol.Circulation . 1994 (6)

[1] 节假日对ST段抬高心肌梗死院内再灌注延迟的影响 [J]. 中国介入心脏病学杂志, 2008, (02) : 91 - 94

[2] 中国ST段抬高的急性心肌梗死临床特征及治疗现状 [J]. 中华医学杂志, 2005, (31) : 2176 - 2182

[3] Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction （CARESS-in-AMI）: an open, prospective, randomised, multicentre trial[J] . Carlo Di Mario,Dariusz Dudek,Federico Piscione,Waldemar Mielecki,Stefano Savonitto,Ernesto Murena,Konstantinos Dimopoulos,Antonio Manari,Achille Gaspardone,Andrzej Ochala,Krzysztof Zmudka,Leonardo Bolognese,Philippe Gabriel Steg,Marcus Flather.The Lancet . 2

[4] Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction[J] . Harindra C. Wijeysundera,Ram Vijayaraghavan,Brahmajee K. Nallamothu,JoAnne M. Foody,Harlan M. Krumholz,Christopher O. Phillips,Amir Kashani,John J. You,Jack V. Tu,Dennis T. Ko.Journal of the American College of Cardiology . 2007 (4)

[5] A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: The TUCC trial[J] . Allan M. Ross,Runlin Gao,Karin S. Coyne,Jilin Chen,Kangbao Yao,Yuejin Yang,Xuewen Qin,Shubin Qiao,Min Yao.American Heart Journal . 2001 (2)

[6] Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial[J] . The Lancet . 2001 (9296)

[7] Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial[J] . The Lancet . 2001 (9272)

[8] Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction[J] . The Lancet . 2001 (9282)

[9] Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999[J] . William J. Rogers,John G. Canto,Costas T. Lambrew,Alan J. Tiefenbrunn,Becky Kinkaid,David A. Shoultz,Paul D. Frederick,Nathan Every.Journal of the American College of Cardiology . 2000 (7)

[10] Mortality Within 24 Hours of Thrombolysis for Myocardial Infarction: The Importance of Early Reperfusion[J] . Neal S. Kleiman,Harvey D. White,E. Magnus Ohman,Allan M. Ross,Lynn H. Woodlief,Robert M. Califf,David R. Holmes,Eric Bates,Matthias Pfisterer,Alec Vahanian,Eric J. Topol.Circulation . 1994 (6)